亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

医学 克里唑蒂尼 肺癌 吉非替尼 培美曲塞 埃罗替尼 卡铂 ROS1型 肿瘤科 靶向治疗 内科学 阿法替尼 癌症研究 间变性淋巴瘤激酶 癌症 化疗 表皮生长因子受体 腺癌 顺铂 恶性胸腔积液
作者
Kathryn C. Arbour,Gregory J. Riely
出处
期刊:JAMA [American Medical Association]
卷期号:322 (8): 764-764 被引量:1121
标识
DOI:10.1001/jama.2019.11058
摘要

Importance: Non-small cell lung cancer remains the leading cause of cancer death in the United States. Until the last decade, the 5-year overall survival rate for patients with metastatic non-small cell lung cancer was less than 5%. Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-targeted therapies and led to improvements in overall survival for patients with advanced or metastatic disease. Observations: Systemic therapy for metastatic non-small cell lung cancer is selected according to the presence of specific biomarkers. Therefore, all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1 (programmed death ligand 1). Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer. Targeted therapy for these alterations improves progression-free survival compared with cytotoxic chemotherapy. For example, somatic activating mutations in the EGFR gene are present in approximately 20% of patients with advanced non-small cell lung cancer. Tyrosine kinase inhibitors such as gefitinib, erlotinib, and afatinib improve progression-free survival in patients with susceptible EGFR mutations. In patients with overexpression of ALK protein, the response rate was significantly better with crizotinib (a tyrosine kinase inhibitor) than with the combination of pemetrexed and either cisplatin or carboplatin (platinum-based chemotherapy) (74% vs 45%, respectively; P < .001) and progression-free survival (median, 10.9 months vs 7.0 months; P < .001). Subsequent generations of tyrosine kinase inhibitors have improved these agents. For patients without biomarkers indicating susceptibility to specific targeted treatments, immune checkpoint inhibitor-containing regimens either as monotherapy or in combination with chemotherapy are superior vs chemotherapy alone. These advances in biomarker-directed therapy have led to improvements in overall survival. For example, the 5-year overall survival rate currently exceeds 25% among patients whose tumors have high PD-L1 expression (tumor proportion score of ≥50%) and 40% among patients with ALK-positive tumors. Conclusions and Relevance: Improved understanding of the biology and molecular subtypes of non-small cell lung cancer have led to more biomarker-directed therapies for patients with metastatic disease. These biomarker-directed therapies and newer empirical treatment regimens have improved overall survival for patients with metastatic non-small cell lung cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
霜序完成签到,获得积分10
5秒前
sunny发布了新的文献求助10
5秒前
萧雨墨发布了新的文献求助10
7秒前
Vicky完成签到,获得积分10
15秒前
神勇的天问完成签到 ,获得积分10
15秒前
萧雨墨发布了新的文献求助10
18秒前
18秒前
20秒前
22秒前
Sarah发布了新的文献求助10
28秒前
笑点低的丹蝶完成签到,获得积分10
29秒前
33秒前
完美世界的应助被Sarah采纳,获得10
36秒前
南尧z完成签到 ,获得积分10
38秒前
华仔的应助被晚风采纳,获得10
41秒前
霸气的似狮完成签到,获得积分10
42秒前
3D完成签到,获得积分10
48秒前
陨石拿铁完成签到,获得积分10
49秒前
xx完成签到 ,获得积分10
51秒前
水长聿完成签到,获得积分10
52秒前
52秒前
avoidant完成签到,获得积分10
57秒前
Maestro_S的应助被尊敬的芷卉采纳,获得10
58秒前
59秒前
fuz发布了新的文献求助10
1分钟前
yl完成签到 ,获得积分10
1分钟前
晚风发布了新的文献求助10
1分钟前
如梦如画完成签到,获得积分10
1分钟前
明理冰海完成签到,获得积分10
1分钟前
fuz完成签到,获得积分20
1分钟前
科研通AI6.4的应助被dart1023采纳,获得10
1分钟前
imcwj完成签到 ,获得积分10
1分钟前
1分钟前
情怀的应助被晚风采纳,获得10
1分钟前
月亮完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被萧雨墨采纳,获得10
1分钟前
朱雀发布了新的文献求助10
1分钟前
1分钟前
辛勤的涵菡完成签到,获得积分10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818